CADTH Appoints New Members to Expert and Advisory Committees  

CADTH has appointed new members to its 3 expert review committees: the Canadian Drug Expert Committee, the pan-Canadian Oncology Drug Review Expert Review Committee, and the Health Technology Expert Review Panel. CADTH has also appointed new members to its Post-Market Drug Evaluation Advisory Committee.  

“These committees play a vital role in helping power evidence-informed drug and health technology decisions in Canada and I’m delighted to welcome our new members,” said Suzanne McGurn, CADTH President and CEO. “Their work as committee members is grounded in science, informed by their skills and experience, and has a direct impact on the lives of people across Canada.”   

CADTH’s expert and advisory committee members have practical health system and clinical experience and/or expertise in a range of fields, including medical ethics, health technology assessment, health economics, epidemiology, and reimbursement policy. CADTH held a public call for nominations for these roles in March 2023 and new members have been appointed for 3-year terms.   

The complete list of members of each committee is available on our website.  

Canadian Drug Expert Committee  

The following individuals have been appointed as members, effective October 1, 2023:  

• Dr. Trudy Huyghebaert, Clinical Pharmacist for the Department of Family Medicine at the University of Calgary, Alberta Health Services; active clinical practitioner; involved with medical resident education and quality improvement projects; preceptor for PharmD students for the University of Alberta and University of Toronto; and Clinical Assistant Professor in the Department of Family Medicine, Cumming School of Medicine, University of Calgary  
• Dr. Peter Jamieson, Clinical Professor in the Cumming School of Medicine, University of Calgary; practicing family physician and hospitalist; and Associate Medical Director for Clinical Operations for Alberta Health Services  
• Dr. Edward Xie, Emergency Physician at University Health Network and an assistant professor in the Department of Family and Community Medicine at the University of Toronto  

CADTH also thanks the following members who concluded their terms of office: Alun Edwards, Allan Grill, and Heather Neville.   

pan-Canadian Oncology Drug Review Expert Review Committee  

The following individuals have been appointed as members, effective October 1, 2023:  

• Dr. Phillip Blanchette, Medical Oncologist at the London Regional Cancer Program, London Health Sciences Centre; Associate Professor of Oncology at the University of Western Ontario; adjunct scientist at the Institute of Clinical Evaluative Sciences (ICES); and active member of Ontario Health’s breast cancer clinical practice guideline and drug advisory committees  
• Dr. Kelvin Chan, Medical Oncologist at the Sunnybrook Hospital’s Odette Cancer Centre; professor at the University of Toronto; and Associate Scientist at the Sunnybrook Research Institute  
• Jennifer Fishman, Associate Professor in the Biomedical Ethics Unit and the Department of the Social Studies of Medicine and associate member of the Sociology Department and the Institute for Health and Social Policy at McGill University 
• Terry Hawrysh, blood cancer survivor; Vice-Chair of the Ontario Institute of Cancer Research Patient Family Advisory Committee; patient partner and patient advisor to the Ottawa Hospital Research Institute, Clinical Trials Ontario, the Leukemia Lymphoma Society of Canada, the University of Toronto’s Centre for Sustainable Health Systems, and Ontario Health; and professional engineer   
• Dr. Yoo-Joung Ko, Medical Oncologist, St. Michael’s Hospital, Unity Health; Associate Professor, Faculty of Medicine, University of Toronto; and Program Medical Director of Unity Health’s Oncology and Endoscopy Program 

CADTH thanks the following members who concluded their terms of office: Jennifer Bell, Winson Cheung, Leela John, and Cam Lane.  

Health Technology Expert Review Panel  

The following individuals have been appointed as members, effective October 1, 2023:  

• Brian Chan, Affiliate Scientist at KITE, the Toronto Rehabilitation Institute, University Health Network, and an assistant professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto  
• Duncan Steele, Alberta Health Services’ Organizational Ethicist   

Post-Market Drug Evaluation Advisory Committee

The following individuals have been appointed as members:  

• Mélanie Caron, Assistant Director, Drug and Technology Reimbursement Review Directorate, INESSS
• Dr. Josee-Lyne Ethier, Medical Oncologist at the Cancer Centre of Southeastern Ontario and Associate Professor at Queen’s University in the Department of Oncology  
• Dr. Tijana Fazlagic, Executive Director, Therapeutic Assessment & Access Branch, BC Ministry of Health
• Dr. Nicole Look Hong, Surgical Oncologist; Associate Professor in the Department of Surgery at the University of Toronto; and faculty at Sunnybrook Health Sciences Centre in the Division of General Surgery  

Quick Facts  

Canadian Drug Expert Committee — an appointed, pan-Canadian expert committee that issues reimbursement recommendations for non-oncology drugs to the participating federal, provincial, and territorial publicly funded drug plans.  

Pan-Canadian Oncology Drug Review Expert Review Committee — an appointed, pan-Canadian expert committee that issues reimbursement recommendations for oncology drugs to the participating federal, provincial, and territorial publicly funded drug plans.  

Health Technology Expert Review Committee — an appointed, pan-Canadian expert committee that issues guidance and/or recommendations on the appropriate use of nondrug health technologies, such as medical devices, surgical procedures, diagnostic tests, and other clinical interventions.  

Post-Market Drug Evaluation Advisory Committee — a multidisciplinary advisory body that provides strategic advice to CADTH on postmarket drug research questions, strategic initiatives, and key priorities.